Heat Biologics Inc.

6.58-0.2000-2.95%Vol 406.88K1Y Perf 61.82%
Apr 15th, 2021 16:00 DELAYED
BID6.47 ASK6.58
Open6.83 Previous Close6.78
Pre-Market6.58 After-Market-
 - -%  - -
Target Price
23.60 
Analyst Rating
Strong Buy 1.00
Potential %
258.66 
Finscreener Ranking
★★★★★ —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★+     59.06
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     64.37
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap167.20M 
Earnings Rating
Neutral
Price Range Ratio 52W %
11.58 
Earnings Date
21st May 2021

Today's Price Range

6.466.92

52W Range

3.5030.10

5 Year PE Ratio Range

-0.3000-1.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-11.32%
1 Month
-21.39%
3 Months
3.79%
6 Months
-27.13%
1 Year
61.82%
3 Years
439.34%
5 Years
-7.32%
10 Years
-

TickerPriceChg.Chg.%
HTBX6.58-0.2000-2.95
AAPL134.502.47001.87
GOOG2 296.6641.82001.85
MSFT259.503.91001.53
XOM56.98-0.3400-0.59
WFC42.240.25000.60
JNJ160.390.47000.29
FB307.825.00001.65
GE13.55-0.1300-0.95
JPM152.170.96000.63
Financial StrengthValueIndustryS&P 500US Markets
30.60
31.10
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-498.10
-491.20
-1 306.60
-
RevenueValueIndustryS&P 500US Markets
2.05M
0.08
3.98
-
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.28-0.42-50.00
Q02 2020-0.56-0.3537.50
Q01 2020--0.77-
Q03 2019-1.12-1.120.00
Q02 2019-0.15-0.146.67
Q01 2019--0.17-
Q03 2018-0.06-0.16-166.67
Q02 2018-0.18-0.23-27.78
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.37-8.82Negative
12/2020 FY-1.23-2.50Negative
3/2021 QR-0.2881.82Positive
12/2021 FY-1.08-0.93Negative
Next Report Date21st May 2021
Estimated EPS Next Report-0.29
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume406.88K
Shares Outstanding25.41M
Trades Count3.20K
Dollar Volume8.23M
Avg. Volume2.22M
Avg. Weekly Volume454.69K
Avg. Monthly Volume431.41K
Avg. Quarterly Volume2.43M

Heat Biologics Inc. (NASDAQ: HTBX) stock closed at 6.58 per share at the end of the most recent trading day (a -2.95% change compared to the prior day closing price) with a volume of 408.77K shares and market capitalization of 167.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Heat Biologics Inc. CEO is Jeffrey Wolf.

The one-year performance of Heat Biologics Inc. stock is 61.82%, while year-to-date (YTD) performance is 22.76%. HTBX stock has a five-year performance of -7.32%. Its 52-week range is between 3.5 and 30.1, which gives HTBX stock a 52-week price range ratio of 11.58%

Heat Biologics Inc. currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 1.60, a price-to-sale (PS) ratio of 85.94, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.17%, a ROC of -33.09% and a ROE of -39.77%. The company’s profit margin is -%, its EBITDA margin is -491.20%, and its revenue ttm is $2.05 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from Heat Biologics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.29 for the next earnings report. Heat Biologics Inc.’s next earnings report date is 21st May 2021.

The consensus rating of Wall Street analysts for Heat Biologics Inc. is Strong Buy (1), with a target price of $23.6, which is +258.66% compared to the current price. The earnings rating for Heat Biologics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Heat Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Heat Biologics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.28, ATR14 : 0.91, CCI20 : -125.47, Chaikin Money Flow : -0.17, MACD : -0.35, Money Flow Index : 28.26, ROC : -7.06, RSI : 44.69, STOCH (14,3) : 9.80, STOCH RSI : 0.00, UO : 39.39, Williams %R : -90.20), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Heat Biologics Inc. in the last 12-months were: Edward Smith (Sold 103 304 shares of value $106 403 ), William L. Ostrander (Option Excercise at a value of $8 125)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Heat Biologics Inc.

Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells that secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.

CEO: Jeffrey Wolf

Telephone: +1 919 240-7133

Address: 627 Davis Drive, Morrisville 27560, NC, US

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

57%43%

Bearish Bullish

56%44%

News

Stocktwits